Sample Category Title
Conferences and events
Sustainability, AI and resilience take centre stage at CPHI Milan 2026
This year’s CPHI conference in Europe will introduce a new sustainability summit, as well as exhibitor zones focusing on AI, contamination control and logistics.
CPHI...
Clinical Trials Insights
Novo Nordisk provides update on a phase 3 trial in people with ASCVD, CKD and inflammation
Novo Nordiskhas announced headline results from the cardiovascular outcomes from a phase 3 trial.
While ziltivekimab demonstrated target engagement and inhibition of the IL-6 pathway,...
Clinical Trials Insights
Kodiak Sciences completes enrolment in first pivotal cohort in the phase 3 trial of KSI-101 for macular oedema secondary to inflammation and reaffirms topline...
Kodiak Sciences Inc. has completed enrolment of the first 300-patient cohort in its clinical trial, supporting pivotal analysis of the KSI-101 phase 3 programme...
Pharma Lab products
ILC Dover introduces EZJetFlo technology to transform powder dissolution and mixing in biopharmaceutical manufacturing
ILC Dover, an Ingersoll Rand business and world leader in the innovative design and production for biopharmaceutical, pharmaceutical, and medical device markets, has announced...
Drug Discovery & Development
Aureka Biotechnologies raises US$100 million to build a biological world model for drug discovery
Aureka Biotechnologies has closed financing of US$100 million.
The company will direct proceeds primarily toward research and large-scale training of its next generation of biological...
Drug Discovery & Development
Oncoinvent announces publication of normal tissue dosimetry results in Journal of Nuclear Medicine
Oncoinvent, a biotech company developing a receptor-independent alpha radiopharmaceutical to eradicate cancer cells in the abdominal cavity after surgery with a single, targeted dose,...
Pharma Lab news
Roche expands cyclospora testing portfolio to support US public health response
As a cyclospora outbreak continues to spread throughout the United States, Roche, in collaboration with subsidiary TIB MOLBIOL, has made available two new flexible and...
Drug Discovery & Development
US FDA approves Takeda’s Orzeyful (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1
The US Food and Drug Administration (FDA) has approved Takeda’s Orzeyful (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy...
- Advertisement -
- Advertisement -
- Advertisement -
- Advertisement -
Latest stories
© 2026 Pharma Press Publishing.